Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
Dilip Shanghvi on Sun-Ranbaxy Deal (interviewer asks stupid questions) -> Link
Why Ranbaxy acquisition is a game-changer for SUN
- Ranbaxy is currently a distressed asset with USFDA issues and the current sales is very low compared to its true potential due to the fda ban on many of its plants
- Ranbaxy sells in >100 markets in the world including many growing emerging markets. So SUN can cross-sell its products in these markets piggybacking on Ranbaxy already established sales/distribution channels
- Ranbaxy has pipeline of 40+ ANDA including high value FTF's like Nexium
- Ranbaxy even has branded products in the developed markets. SUN is good at capitalizing full sales potential for sole-competitor/low-competitor assets.
Ranbaxy's US Derma Products
We have a major focus in Dermatology with a presence across markets, including the US, India and Brazil. We have a robust franchise in the Corticosteroids, Anti-infectives and Anti-acne segments. Our current portfolio in the US caters to both prescription and consumer driven Over-the-Counter (OTC) markets, the major brands being Ultravate, Kenalog and Lac Hydrin. We have the global licensing rights to market Luliconazole (a novel Anti-fungal) in 16 markets, including India, Malaysia, Singapore and South Africa.Quote
Ranbaxty's Absorbica US sales were ~$60m.-> http://articles.economictimes.indiatimes.com/2013-11-26/news/44487256_1_ranbaxy-laboratories-absorica-usfda
Quote: Acne drug Absorica, a generic version of isotretinoin, has been gaining market share since its launch in December 2012. The drug has a total market size of $1 billion (at the price of Absorica), which is growing at almost 15% annually. Absorica's market share in October was 19% and analysts expect it to touch around 24% by the end of 2013-14, given Ranbaxy's 30-month exclusivity period.
If you like to receive free updates on stocks directly to your email inbox, click on the subscribe via mail icon situated on the top right of this blog.